Erectile Function Outcome Reporting After Clinically Localized Prostate Cancer Treatment

Burnett, Arthur L.; Aus, Gunnar; Canby-Hagino, Edith D.; Cookson, Michael S.; D’Amico, Anthony V.; Dmochowski, Roger R.; Eton, David T.; Forman, Jeffrey D.; Goldenberg, S. Larry; Hernandez, Javier; Higano, Celestia S.; Kraus, Stephen; Liebert, Monica; Moul, Judd W.; Tangen, Catherine; Thrasher, J. Brantley; Thompson, Ian; American Urological Association Prostate Cancer Guideline Update Panel,

doi:10.1016/j.juro.2007.03.140

« Previous Next »The Journal of Urology
Volume 178, Issue 2 , Pages 597-601, August 2007

Erectile Function Outcome Reporting After Clinically Localized Prostate Cancer Treatment

Arthur L. Burnett
- Correspondence: The Johns Hopkins Hospital, 600 North Wolfe St., Marburg 407, Baltimore, Maryland 21287-2411 (telephone: 410-614-3986; FAX: 410-614-3695).
- Financial interest and/or other relationship with Pfizer, Lilly ICOS and Guilford/MGI Pharma.
Gunnar Aus
Edith D. Canby-Hagino
Michael S. Cookson
- Financial interest and/or other relationship with Sanofi-Aventis, GlaxoSmithKline, Envisioneering Medical Technologies, Aeterna Zentaris Solvay, Photocure, National Institutes of Health and GTX.
Anthony V. D’Amico
Roger R. Dmochowski
- Financial interest and/or other relationship with Indevus, Watson Pharmaceuticals and Bard.
David T. Eton
Jeffrey D. Forman
S. Larry Goldenberg
Javier Hernandez
Celestia S. Higano
Stephen Kraus
- Financial interest and/or other relationship with National Institute for Diabetes and Digestive and Kidney Diseases, Pfizer, Astellas, Novartis and Ortho McNeil.
Monica Liebert
Judd W. Moul
Catherine Tangen
J. Brantley Thrasher
Ian Thompson
- Financial interest and/or other relationship with Mission Pharmacal, AstraZeneca and National Institutes of Health.
American Urological Association Prostate Cancer Guideline Update Panel

Received 27 December 2006 published online 13 June 2007.

Purpose

In conjunction with the assignment to update the Guidelines for Management of Clinically Localized Prostate Cancer, the American Urological Association Prostate Cancer Guideline Update Panel performed a side analysis of the reporting of erectile function outcomes in this clinical context as published in the medical literature.

Materials and Methods

Four National Library of Medicine PubMed® Services literature searches targeting articles published from 1991 through early 2004 were done to derive outcome reporting (efficacy or side effects) for the treatment of clinical stage T1 or T2 N0M0 prostate cancer. A database was constructed containing descriptions relating to erectile function as well as numerical frequency rates of complete erectile dysfunction, and partial and intact erectile function for various treatments. A literature review was also done, consisting of a PubMed Services search of current measures and protocols used for assessing erectile function outcomes and a survey of consensus opinion sources on the management of male sexual dysfunctions.

Results

Based on inclusion criteria 436 articles were selected. Of these articles database extraction from 100 pertaining to radical prostatectomy garnered various characterizations of erectile function, including qualitative descriptions, generic terminology and rating systems. Database extraction from 31 articles, in which results for at least 50 patients were reported, yielded ranges of rates for complete erectile dysfunction, partial erectile function and intact erectile function that were 26% to 100%, 16% to 48% and 9% to 86% for radical prostatectomy, 8% to 85%, 21% to 47% and 36% to 63% for external beam radiation, and 14% to 61%, 21% and 18% for interstitial radiation, respectively. The literature review showed an evolution in standards for studying and reporting erectile function outcomes.

Conclusions

Clinical studies reporting erectile function outcomes after localized prostate cancer treatment often demonstrate poorly interpretable and inconsistent manners of assessment as well as widely disparate rates of erectile dysfunction and erectile function. Future studies must apply scientifically rigorous methodology and standard outcomes measures to advance this field of study.

Key Words: penis, impotence, prostate, prostatic neoplasms, quality of life

Abbreviations and Acronyms: AUA, American Urological Association, ED, erectile dysfunction, EF, erectile function, IIEF, International Index of Erectile Function